TY  - JOUR
A1  - Brunkhorst-Kanaan, Nathalie
A1  - Trautmann, Sandra
A1  - Schreiber, Yannick
A1  - Thomas, Dominique Jeanette
A1  - Kittel-Schneider, Sarah
A1  - Gurke, Robert
A1  - Geisslinger, Gerd
A1  - Reif, Andreas
A1  - Tegeder, Irmgard
T1  - Sphingolipid and endocannabinoid profiles in adult attention deficit hyperactivity disorder
T2  - Biomedicines
N2  - Genes encoding endocannabinoid and sphingolipid metabolism pathways were suggested to contribute to the genetic risk towards attention deficit hyperactivity disorder (ADHD). The present pilot study assessed plasma concentrations of candidate endocannabinoids, sphingolipids and ceramides in individuals with adult ADHD in comparison with healthy controls and patients with affective disorders. Targeted lipid analyses of 23 different lipid species were performed in 71 mental disorder patients and 98 healthy controls (HC). The patients were diagnosed with adult ADHD (n = 12), affective disorder (major depression, MD n = 16 or bipolar disorder, BD n = 6) or adult ADHD with comorbid affective disorders (n = 37). Canonical discriminant analysis and CHAID analyses were used to identify major components that predicted the diagnostic group. ADHD patients had increased plasma concentrations of sphingosine-1-phosphate (S1P d18:1) and sphinganine-1-phosphate (S1P d18:0). In addition, the endocannabinoids, anandamide (AEA) and arachidonoylglycerol were increased. MD/BD patients had increased long chain ceramides, most prominently Cer22:0, but low endocannabinoids in contrast to ADHD patients. Patients with ADHD and comorbid affective disorders displayed increased S1P d18:1 and increased Cer22:0, but the individual lipid levels were lower than in the non-comorbid disorders. Sphingolipid profiles differ between patients suffering from ADHD and affective disorders, with overlapping patterns in comorbid patients. The S1P d18:1 to Cer22:0 ratio may constitute a diagnostic or prognostic tool.
KW  - attention deficit hyperactivity disorder
KW  - endocannabinoids
KW  - ceramides
KW  - bipolar disorder
KW  - major depression
KW  - tandem mass spectrometry
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63448
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-634487
SN  - 2227-9059
N1  - The study was supported by the Deutsche Forschungsgemeinschaft, DFG (CRC1039, A03 to IT and CRC1039, Z01 to GG; CRC1080 C02 to I.T.) and by the Fraunhofer Cluster of Excellence for immune mediated diseases (CIMD, to GG). The funders had no role in the collection, analyses, and interpretation of data, writing of the manuscript, or the decision to submit the article for publication.
VL  - 9
IS  - 9, art. 1173
SP  - 1
EP  - 15
PB  - MDPI
CY  - Basel
ER  -